Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Buxtehude

1 242 clinical trials in Buxtehude, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Buxtehude at a glance
1 242
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 242 trials in Buxtehude

Open in trial search

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:TAK-019
  • Sponsor:Sanofi Pasteur Inc.

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atebimetinib
  • Sponsor:Immuneering Corp.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Buxtehude

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical trials focusing on moderate to severe atopic dermatitis and plaque psoriasis, evaluating novel treatments including amlitelimab, eblasakimab, and ESK-001. Research aims to assess treatment efficacy and long-term safety profiles.

  • Atopic Dermatitis Studies
  • Psoriasis Research
  • Treatment Response Assessment

Multiple studies examining maintenance therapy and dose optimization in chronic skin conditions.

02 Melanoma Research

Comprehensive studies evaluating advanced melanoma treatments, including adjuvant immunotherapy trials with pembrolizumab and novel combination therapies. Research focuses on both early-stage and metastatic disease.

  • Stage III/IV Melanoma
  • Immunotherapy Combinations
  • Disease-Free Survival

Emphasis on developing more effective treatment strategies for high-risk melanoma patients.

03 Rare Dermatological Conditions

Investigating treatments for chronic urticaria, hidradenitis suppurativa, and bullous pemphigoid. Studies evaluate innovative therapies including remibrutinib and dupilumab for these challenging conditions.

  • Chronic Urticaria Management
  • Autoimmune Skin Disorders
  • Novel Therapeutic Approaches

Focus on improving treatment outcomes for patients with resistant disease forms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.